One of Merck’s next-generation pneumococcal vaccines has sailed through a mid-stage trial and is being readied for a Phase III study in July.
[Fierce Biotech]
Home Newsletters Immunology of Infectious Disease News Merck’s Next-Gen Pneumococcal Vaccine Slated for July Phase III after Two-Part Win
